The global artificial intelligence for drug discovery and development market size was valued at USD 2.4 billion in 2025 and is projected to grow from USD 3.12 billion in 2026 to USD 25.28 billion by 2034, registering a CAGR of 29.9% during the forecast period from 2026 to 2034. North America dominated the artificial intelligence for drug discovery and development market with a market share of 41.5% in 2025.
Artificial intelligence for drug discovery and development involves using AI technologies such as machine learning and deep learning to identify drug candidates, predict their properties, optimize compounds, and support clinical research. It helps pharmaceutical and biotechnology companies reduce development time, improve research accuracy, and lower costs. Adoption is growing due to increasing R&D investments, large biomedical datasets, and demand for faster and more efficient drug development.
Download a Free Sample To learn more about this report,
Growing Use of AI for Faster Drug Candidate Identification
Artificial intelligence for drug discovery and development market trends are being driven by the increasing use of machine learning and generative AI to identify promising drug candidates more quickly. Pharmaceutical and biotechnology companies are using AI to analyze large biological and chemical datasets, predict molecular interactions, identify potential drug targets, and optimize compounds before laboratory testing. This approach can reduce the time spent screening thousands of molecules and help researchers prioritize candidates with stronger potential. These developments are supporting artificial intelligence for drug discovery and development market growth as companies look for faster and more efficient approaches to pharmaceutical R&D.
Rising Adoption of Generative AI and Strategic Pharma-AI Partnerships
Generative AI is becoming increasingly important for designing novel molecules, predicting protein structures, and optimizing potential drug compounds. Pharmaceutical companies are also forming partnerships with specialized AI firms to combine clinical and biological data with advanced computational models. These collaborations can improve target identification, drug repurposing, and preclinical research while reducing dependence on traditional trial-and-error methods. AI platforms are also becoming more integrated across different stages of the development process. These advancements are strengthening artificial intelligence for drug discovery and development market share by expanding the practical use of AI across pharmaceutical research.
Growing Need to Reduce Drug Development Time and Costs
The artificial intelligence for drug discovery and development market is growing rapidly as pharmaceutical and biotechnology companies look for faster and more efficient ways to identify promising drug candidates. AI can analyze large biological and chemical datasets, predict molecular interactions, identify potential targets, and support compound screening. These capabilities can reduce repetitive laboratory work and improve early-stage decision-making. Increasing pharmaceutical R&D investment is strengthening artificial intelligence for drug discovery and development market demand.
Limited High-Quality Data and High Implementation Costs
The artificial intelligence for drug discovery and development market faces restraints because effective AI models depend on large amounts of reliable and well-structured scientific data. Incomplete datasets, inconsistent experimental results, and limited access to proprietary pharmaceutical information can reduce model accuracy. Companies also require advanced computing infrastructure and skilled professionals, increasing implementation costs.
Expansion of Generative AI and Precision Drug Discovery
The artificial intelligence for drug discovery and development market offers strong opportunities as generative AI becomes more capable of designing novel molecules and predicting their properties. AI can also combine genomic, clinical, and molecular information to support precision medicine and identify treatments for specific patient populations. Growing partnerships between pharmaceutical companies and AI developers are expected to strengthen artificial intelligence for drug discovery and development market share.
Validating AI Predictions in Clinical and Laboratory Settings
The artificial intelligence for drug discovery and development market continues to face challenges because AI-generated predictions must still be confirmed through laboratory experiments, preclinical studies, and clinical trials. A promising computational result does not guarantee that a drug will be safe or effective in humans. Companies must also improve model transparency and meet evolving regulatory expectations for AI-supported research.
Request Customizationto receive a tailored report.
Drug Optimisation and Repurposing Segment Dominated the Market with 47.6% Share in 2025
The drug optimisation and repurposing segment dominated the global artificial intelligence for drug discovery and development market with a 47.6% share in 2025. AI technologies help researchers analyze large datasets, identify promising drug candidates, predict molecular interactions, and discover new therapeutic uses for existing drugs. These capabilities can reduce development time and improve the efficiency of drug research, supporting the segment's leading position.
The preclinical testing segment is also growing rapidly as AI models are increasingly used to predict drug toxicity, efficacy, and biological responses before clinical trials. The others segment continues to expand through applications such as target identification, molecular design, and clinical research support. Increasing adoption of AI across pharmaceutical R&D is expected to support all application segments.
Oncology Segment Dominated the Market with 38.7% Share in 2025
The oncology segment dominated the global artificial intelligence for drug discovery and development market with a 38.7% share in 2025. AI is increasingly used in cancer research to identify therapeutic targets, analyze complex biological data, discover drug candidates, and support the development of precision treatments. Strong investment in oncology research and growing demand for targeted therapies continue to strengthen the segment's leading position.
The neurodegenerative diseases segment is also witnessing strong growth as researchers use AI to study complex conditions and identify potential treatments for neurological disorders. Infectious disease applications continue to expand as AI helps analyze pathogens, identify drug targets, and accelerate therapeutic discovery.
The others segment also contributes through research across cardiovascular, metabolic, autoimmune, and rare diseases. Expanding AI capabilities are expected to support drug discovery across all therapeutic areas.
Pharmaceutical & Biotechnology Segment Dominated the Market with 61.8% Share in 2025
The pharmaceutical & biotechnology segment dominated the global artificial intelligence for drug discovery and development market with a 61.8% share in 2025. Pharmaceutical and biotechnology companies increasingly integrate AI into research workflows to improve target identification, optimize compounds, analyze biological data, and reduce the time required for drug development. Growing investment in AI-powered research platforms continues to support the segment's leading position.
The CRO segment is also expanding rapidly as pharmaceutical companies increasingly outsource research activities to organizations with specialized AI capabilities and drug development expertise. AI-enabled CRO services can support candidate screening, preclinical research, data analysis, and other development activities.
The others segment continues to grow through adoption among academic institutions, research organizations, and specialized technology providers. Increasing collaboration between life sciences companies and AI developers is expected to support long-term growth across all end-use segments.
Speak to an Analystto discuss market opportunities.
North America artificial intelligence for drug discovery and development market accounted for 41.5% of the global market, reaching USD 1.00 billion in 2025, and is projected to grow at a CAGR of 28.9% during the forecast period. Strong pharmaceutical and biotechnology research, increasing investment in AI-based drug development platforms, and growing collaboration between technology companies and drug manufacturers are supporting regional growth. AI is increasingly being used to identify drug targets, optimize compounds, and shorten development timelines.
The US market was valued at USD 0.85 billion in 2025, making it the largest contributor in North America. Strong biotechnology investment, widespread adoption of AI in pharmaceutical R&D, and increasing partnerships between technology and life sciences companies continue to support market growth.
Canada's market reached USD 0.15 billion in 2025. Growing AI research capabilities, expanding biotechnology activities, and increasing investment in computational drug discovery are supporting market development.
Europe artificial intelligence for drug discovery and development market accounted for 27.2% of the global market, reaching USD 0.65 billion in 2025, and is expected to register a CAGR of 27.8% during the forecast period. Strong pharmaceutical research, increasing adoption of machine learning in drug development, and growing investment in computational biology are supporting market expansion. Research institutions and pharmaceutical companies are increasingly collaborating to accelerate the identification and development of new therapies.
Germany's market accounted for USD 0.19 billion in 2025. A strong pharmaceutical and biotechnology sector, increasing AI research, and growing investment in digital drug development technologies continue to support market growth.
The UK market was valued at USD 0.13 billion in 2025. Strong life sciences research, a growing AI ecosystem, and increasing collaboration between biotechnology companies and research institutions continue to contribute to market expansion.
Asia Pacific artificial intelligence for drug discovery and development market accounted for 21.8% of the global market, valued at USD 0.52 billion in 2025, and is projected to register a CAGR of 32.4% during the forecast period. Rapid expansion of pharmaceutical research, increasing investment in artificial intelligence, and growing availability of healthcare and genomic data are driving regional growth. Pharmaceutical companies are increasingly adopting AI tools to improve drug screening, target identification, and clinical development.
Japan's market generated USD 0.09 billion in 2025. Strong pharmaceutical research capabilities, increasing adoption of AI technologies, and growing investment in advanced drug discovery platforms continue to support market growth.
China's market accounted for USD 0.27 billion in 2025, making it a major contributor within Asia Pacific. Rapid growth of biotechnology companies, increasing AI investment, and expanding pharmaceutical R&D activities continue to drive market development.
Middle East & Africa artificial intelligence for drug discovery and development market accounted for 4.2% of the global market, reaching USD 0.10 billion in 2025, and is anticipated to grow at a CAGR of 25.4% during the forecast period. Increasing investment in healthcare technology, expanding artificial intelligence capabilities, and growing interest in pharmaceutical research are supporting market development across the region.
The UAE market was valued at USD 0.04 billion in 2025. Increasing investment in artificial intelligence, healthcare innovation, biotechnology research, and digital health infrastructure continues to support the adoption of AI-based drug discovery technologies.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com